Mavrikou Ioulia, Castelli Marta, Touloumenidou Tasoula, Bousiou Zoi, Koravou Evangelia-Evdoxia, Vardi Anna, Papalexandri Apostolia, Demosthenous Christos, Koutra Maria, Evangelidis Paschalis, Panteliadou Alkistis-Kyra, Batsis Ioannis, Chatzidimitriou Dimitrios, Nikolousis Emmanouil, Rambaldi Alessandro, Sakellari Ioanna, Gavriilaki Eleni
Hematology & BMT Unit, General Hospital "George Papanikolaou", 57010 Thessaloniki, Greece.
Hematology and Bone Marrow Transplant Unit, Ospedale Papa Giovanni XXIII, 24127 Bergamo, Italy.
Int J Mol Sci. 2025 Jul 12;26(14):6712. doi: 10.3390/ijms26146712.
Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease (SOS/VOD) is a severe complication of hematopoietic cell transplantation (HCT). Furthermore, emerging evidence suggests the potential role of complement activation and endothelial injury in SOS/VOD pathogenesis. In this study, we aimed to identify potential distinct pathogenic genetic variants between SOS/VOD and other endothelial injury syndromes following HCT, such as transplant-associated thrombotic microangiopathy (TA-TMA). For this aim, genomic DNA from 30 SOS/VOD patients and 30 controls with TA-TMA was analyzed. Using Next-Generation Sequencing (NGS), variants in complement-related genes (CFH, CFI, CFB, CFD, C3, CD55, C5, CD46, and thrombomodulin/THBD) and ADAMTS13 were examined. Out of 426 detected variants, 20 were classified as pathogenic. In SOS/VOD patients, variants were identified in ADAMTS13 (4), CFH (3), C3 (2), and CFB (1) genes. One of the variants has been recognized as the strongest genetic predictor of ADAMTS13 activity. Controls exhibited more variants in complement-related genes, particularly CFH, CFI, and C3. The genetic differences between SOS/VOD and TA-TMA highlight different pathogenic mechanisms, offering the potential for targeted risk assessment and therapy in HCT recipients.
窦性阻塞综合征/静脉闭塞性疾病(SOS/VOD)是造血细胞移植(HCT)的一种严重并发症。此外,新出现的证据表明补体激活和内皮损伤在SOS/VOD发病机制中具有潜在作用。在本研究中,我们旨在确定SOS/VOD与HCT后其他内皮损伤综合征(如移植相关血栓性微血管病(TA-TMA))之间潜在的不同致病基因变异。为此,我们分析了30例SOS/VOD患者和30例TA-TMA对照的基因组DNA。使用下一代测序(NGS)技术,检测了补体相关基因(CFH、CFI、CFB、CFD、C3、CD55、C5、CD46和血栓调节蛋白/THBD)和ADAMTS13中的变异。在检测到的426个变异中,20个被分类为致病性变异。在SOS/VOD患者中,ADAMTS13(4个)、CFH(3个)、C3(2个)和CFB(1个)基因中鉴定出变异。其中一个变异已被认为是ADAMTS13活性最强的遗传预测指标。对照组在补体相关基因中表现出更多变异,尤其是CFH、CFI和C3。SOS/VOD与TA-TMA之间的遗传差异突出了不同的致病机制,为HCT受者的靶向风险评估和治疗提供了可能性。